Gh Research Plc · NASDAQ:GHRS
Gh Research — Investor Presentation (November 2025)
14 slides from Gh Research's investor presentation, Nov 6, 2025
Slide 1: GH Research PLC November 2025 Corporate Presentation
GH Research PLC (NASDAQ: GHRS) November 2025 Corporate Presentation 2025© GH Research PLC 1
Slide 2: Forward-Looking Statements
Any statements contained herein that do not describe historical facts are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those
Slide 3: Pipeline
Product Candidate Indication Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Current Status Milestone GH001 Mebufotenin for inhalation administration Treatment-resistant depression (TRD) Phase 2b RDBPC completed Phase 1 PK trial with proprietary device ongoing Phase 3 initiation in 2026 Phase 1 PK tri
Slide 4: SPRAVATO Has Been Established as a $1-5 Bn Drug in Interventional Psychiatry
SPRAVATO® has Been Established as a $1-5 Bn Drug in Interventional Psychiatry 4 2024 Worldwide Sales: $1.077 Bn 2025 Worldwide Sales (Q1-Q3): $1.193 Bn Estimated annual WAC of $32,400 -4.0 Approved for TRD Monotherapy and in Conjunction with an Oral Antidepressant -4.0 MADRS Points Mean Δ to Control
Slide 5: GH001-TRD-201 Phase 2b Trial Design with Open-Label Extension
5 Retreatment of up to five GH001 IDRs if patients met retreatment criteriaa Open-Label Extension (OLE) N=81 Randomization 1:1 GH001 IDR Placebo IDR BL 2h Day 1 Primary endpoint ΔMADRS Day 8 During the OLE, patients attended visits at Day 15, Month 1, 2, 3, 4, 5 & 6b Additional clinic visits could b
Slide 6: Primary Endpoint: Mean MADRS Reduction of -15.5 on Day 8 vs Placebo
Primary Endpoint: GH001 Led to Mean MADRS Reduction from Baseline of -15.5 on Day 8a vs Placebo (P<0.0001) aFDA Guidance notes that efficacy with rapid-acting antidepressants generally should be demonstrated within 1 week, supporting a primary efficacy endpoint within this timeframe. Abbreviations:
Slide 7: Secondary Endpoint: 57.5% Remission Rate and 60% Response Rate at Day 8
****P<0.0001 2 Hours Day 2 Day 8 Remission Response GH001 Placebo **** **** **** **** **** **** Remission Response Remission Response NNT=2 NNT=2 NNT=2 Remission is defined as a MADRS total score of ≤10. Response is defined as a ≥50% reduction from baseline in MADRS total score. Abbreviations: MADRS
Slide 8: 73% Remission Rate at 6 Months in OLE Completers
8 There was a 73% Remission Rate at 6 Months in OLE Completers aIncludes 63 patients who completed the 6-month OLE per protocol (18 patients terminated early are excluded). bApproximately 6 months post-study start (median 168 days from Day 1 of double-blind part). cRemission defined as MADRS total s
Slide 9: Remission Rate at 6 Months in OLE Completers
Initial Remitters N=40 Initial Non-Remitters N=23 Percentage of Patients in Remissionc 9 Remission Rate at 6 Monthsa in OLE Completersb a‘6 Months’ or ‘Month 6’ (end of trial) was at approximately 6 months post-study start (median 168 days from Day 1 of double-blind part). bIncludes 63 patients who
Slide 10: Summary of Safety in Double-Blind and Open-Label Extension
Abbreviations: OLE = Open-label extension; SAE = Serious adverse event; TEAE = Treatment-emergent adverse event. Summary of Safety in Double-Blind and Open-Label Extension 2025© GH Research PLC All patients completed the double-blind part and automatically transitioned to the OLE No TEAEs of suicida
Slide 11: 83% Fewer Treatment Visits With GH001 Than With Spravato
GH001 Based on ESCAPE-TRD data & ICER estimate Treatment visits in 6 months 4 visitsa 23 visitsc,d 73.0% remission at 6 monthsb 83% Fewer Treatment Visits With GH001 Than With Spravato® Note: To-date, no head-to-head comparisons of any other products to any of our product candidates have been comple
Slide 12: Median Duration of the Psychoactive Experience
Median Duration of the Psychoactive Experience of 11 minutes (Double-Blind & OLE treatments) Note: To-date, no head-to-head comparisons of any other products to any of our product candidates have been completed in any clinical trial; results have been obtained from different trials with different de
Slide 13: Potential Value-Add for GH001 in TRD
Potential Value-Add for GH001 in TRD Best in Therapeutic Category (TRD) Efficacy: Pbo-adj MADRS Δ of -15.5 with GH001 vs -6.8 with Spravato monotherapya vs ~-4 with oral ADb Length of PsE: Median of 11 mins with GH001 vs ~1.5 hours with Spravatoc No additional psychotherapy/therapist visits with GH0
Slide 14: Three-Layer Protection Strategy
Three-Layer Protection Strategy 14 LAYER 1: REGULATORY EXCLUSIVITY FDA: 5 years (+2.5 years paragraph IV stay) EMA: 10 years (+1 year for new indication) LAYER 2: PATENTS Granted patents and patent applications relating to mebufotenin, including: Novel uses in various disorders (including inhaled, n